What is it about?
The macrovascular protective effect of the antihypertensive strategy has been examined in numerous clinical trials, but the anti-microvascular complications associated with current drugs have not been thoroughly reviewed. In this review and meta-analysis, we summarized the currently available data on microvascular safety of drugs through previous clinical studies.
Featured Image
Photo by Swapnil Potdar on Unsplash
Why is it important?
Several safety concerns have recently been raised regarding current and especially new antihyperglycemic drugs. Addressing these issues allows us to achieve optimal glycemic control and offer better, personalized treatment in clinical practice, whether inside or outside the diabetology ward.
Perspectives
Current evidence on how all antihyperglycemic drugs impact microvascular complications remains inconclusive. More real-world data, along with well-designed clinical RCTs and mechanistic studies, are needed to clarify this issue.
Dr. Song Wen
Shanghai Pudong Hospital, Fudan University
Read the Original
This page is a summary of: The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials, BMC Endocrine Disorders, July 2025, Springer Science + Business Media,
DOI: 10.1186/s12902-025-01985-2.
You can read the full text:
Resources
Contributors
The following have contributed to this page
